Drug therapy in stroke: From preclinical to clinical studies

Pharmacology

Volumn 92, Issue 5-6, 2014, Pages 324-334

  Kaur, Harjeet ^a   Prakash, Ajay ^a   Medhi, Bikash ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Cerebral ischemia; Clinical trial; Ischemic stroke; Neuroprotection; Phase III trial

Indexed keywords

4 PHOSPHONOMETHYLPIPECOLIC ACID; ABCIXIMAB; ACETYLSALICYLIC ACID; ALTEPLASE; APTIGANEL; CILOSTAZOL; CLOMETHIAZOLE; CLOPIDOGREL; CROMOGLYCATE DISODIUM; CYCLOSPORIN A; DAPSONE; DISUFENTON SODIUM; DIZOCILPINE; EBSELEN; ENOXAPARIN; EPTIFIBATIDE; FANAPANEL; FIBRINOLYTIC AGENT; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MAGNESIUM SULFATE; NEUROPROTECTIVE AGENT; NIMODIPINE; NORPHENAZONE; STREPTOKINASE; TIRILAZAD; UNINDEXED DRUG; URIC ACID; UROKINASE; ZONAMPANEL; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT;

BLOOD BRAIN BARRIER; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CLINICAL STUDY; DRUG SAFETY; DRUG SCREENING; HUMAN; INDUCED HYPOTHERMIA; MIDDLE CEREBRAL ARTERY OCCLUSION; MULTICENTER STUDY (TOPIC); NEUROPROTECTION; NONHUMAN; PATHOPHYSIOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW (TOPIC); TRANSIENT ISCHEMIC ATTACK; DRUG TARGETING; HYPOTHERMIA; OXIDATIVE PHOSPHORYLATION; RISK FACTOR; STROKE PATIENT;

ANIMALS; BRAIN ISCHEMIA; CLINICAL TRIALS AS TOPIC; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; HUMANS; MOLECULAR TARGETED THERAPY; NEURONS; NEUROPROTECTIVE AGENTS; STROKE; TRANSLATIONAL MEDICAL RESEARCH; WORLD HEALTH;

EID: 84893013706     PISSN: 00317012     EISSN: 14230313     Source Type: Journal    
DOI: 10.1159/000356320     Document Type: Review

References (84)

1. Mackay J, Mensah G: The Atlas of Heart and Stroke. Geneva, World Health Organization, 2004.
2. The World Health Organization MONICA Project (monitoring trends and determinants in cardiovascular disease): A major international collaboration. WHO MONICA Project Principal Investigators. J Clin Epidemiol 1988; 41: 105-114.
3. Writing Group Members, Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, de Simone G, Ferguson TB, Ford E, Furie K, Gillespie C, Go A, Greenlund K, Haase N, Hailpern S, Ho PM, Howard V, Kissela B, Kittner S, Lackland D, Lisabeth L, Marelli A, McDermott MM, Meigs J, Mozaffarian D, Mussolino M, Nichol G, Roger VL, Rosamond W, Sacco R, Sorlie P, Roger VL, Thom T, Wasserthiel- Smoller S, Wong ND, Wylie-Rosett J: Heart disease and stroke statistics - 2010 update: A report from the American Heart Association. Circulation 2010; 121:e46-e215.
4. Murray CJL, Lopez AD: The Global Burden of Disease: A Comprehensive Assessment of Mortality and Disability from Diseases, Injuries, and Risk Factors in 1990 and Projected to 2020. Global Burden of Disease and Injury Series, book 1. Cambridge, Harvard UP, 1996.
5. Edvinsson L, Krause DN: Cerebral Blood Flow and Metabolism. Philadelphia, Lippincott Williams & Wilkins, 2002.
6. Caplan L: Caplan's Stroke: A Clinical Approach. Philadelphia, Saunders Elsevier, 2009.
7. Asahi M, Wang X, Mori T, Sumii T, Jung JC, Moskowitz MA, Fini ME, Lo EH: Effects of matrix metalloproteinase-9 gene knock-out on the proteolysis of blood-brain barrier and white matter components after cerebral ischemia. J Neurosci 2001; 21: 7724-7732.
8. Kincses ZT, Vecsei L: Pharmacological therapy in Parkinson's disease: Focus on neuroprotection. CNS Neurosci Ther 2011; 17: 345-367.
9. Durukan A, Tatlisumak T: Acute ischemic stroke: Overview of major experimental rodent models, pathophysiology, and therapy of focal cerebral ischemia. Pharmacol Biochem Behav 2007; 87: 179-197.
10. O'Collins VE, Macleod MR, Donnan GA, Horky LL, van der Worp BH, Howells DW: 1,026 experimental treatments in acute stroke. Ann Neurol 2006; 59: 467-477.
11. Gladstone DJ, Black SE, Hakim AM: Toward wisdom from failure: Lessons from neuroprotective stroke trials and new therapeutic directions. Stroke 2002; 33: 2123-2136.
12. Cheng YD, Al-Khoury L, Zivin JA: Neuroprotection for ischemic stroke: Two decades of success and failure. NeuroRx 2004; 1: 36-45.
13. Camerlingo M, Salvi P, Belloni G, Gamba T, Cesana BM, Mamoli A: Intravenous heparin started within the first hours after onset of symptoms as a treatment for acute nonlacunar hemispheric cerebral infarctions. Stroke 2005; 36: 2415-2420.
14. Zhang ZG, Lu TS, Yuan HY: Neuroprotective effects of ultra-low-molecular- weight heparin in vitro and vivo models of ischemic injury. Fundam Clin Pharmacol 2011; 25: 300-303.
15. Zhang ZG, Sun X, Zhang QZ, Yang H: Neuroprotective effects of ultra-low-molecularweight heparin on cerebral ischemia/reperfusion injury in rats: Involvement of apoptosis, inflammatory reaction and energy metabolism. Int J Mol Sci 2013; 14: 1932-1939.
16. Mary V, Wahl F, Uzan A, Stutzmann JM: Enoxaparin in experimental stroke: Neuroprotection and therapeutic window of opportunity. Stroke 2001; 32: 993-999.
17. Study on Continuous Intravenous of Unfractionated Heparin (UFH) to Treat Progressive Cerebral Infarction (UHPCI). 2011. http://clinicaltrials.gov/ct2/ show/NCT01378000.
18. Kase CS, Albers GW, Bladin C, Fieschi C, Gabbai AA, O'Riordan W, Pineo GF: Neurological outcomes in patients with ischemic stroke receiving enoxaparin or heparin for venous thromboembolism prophylaxis: Subanalysis of the Prevention of VTE after Acute Ischemic Stroke with LMWH (PREVAIL) study. Stroke 2009; 40: 3532-3540.
19. Nonaka Y, Tsuruma K, Shimazawa M, Yoshimura S, Iwama T, Hara H: Cilostazol protects against hemorrhagic transformation in mice transient focal cerebral ischemia-induced brain damage. Neurosci Lett 2009; 452: 156-161.
20. Ding G, Jiang Q, Zhang L, Zhang ZG, Li L, Knight RA, Ewing JR, Wang Y, Chopp M: Analysis of combined treatment of embolic stroke in rat with r-tPA and a GPIIb/IIIa inhibitor. J Cereb Blood Flow Metab 2005; 25: 87-97.
21. Lee YS, Bae HJ, Kang DW, Lee SH, Yu K, Park JM, Cho YJ, Hong KS, et al: Cilostazol in Acute Ischemic Stroke Treatment (CAIST Trial): A randomized double-blind non-inferiority trial. Cerebrovasc Dis 2011; 32: 65-71.
22. Shinohara Y, Katayama Y, Uchiyama S, Yamaguchi T, Handa S, Matsuoka K, Ohashi Y, et al: Cilostazol for prevention of secondary stroke (CSPS 2): An aspirin-controlled, double- blind, randomised non-inferiority trial. Lancet Neurol 2010; 9: 959-968.
23. Han SW, Lee SS, Kim SH, Lee JH, Kim GS, Kim OJ, Koh IS, et al: Effect of Cilostazol in Acute Lacunar Infarction Based on Pulsatility Index of Transcranial Doppler (ECLIPse): A multicenter, randomized, double-blind, placebocontrolled trial. Eur Neurol 2013; 69: 33-40.
24. Uchiyama S, Sakai N: Cilostazol-Aspirin Therapy against Recurrent Stroke with Intracranial Artery Stenosis. 2006. http://clinicaltrials. gov/show/NCT00333164.
25. Pancioli AM, Broderick J, Brott T, Tomsick T, Khoury J, Bean J, del Zoppo G, et al: The combined approach to lysis utilizing eptifibatide and rt-PA in acute ischemic stroke: The CLEAR stroke trial. Stroke 2008; 39: 3268- 3276.
26. Pancioli AM, Adeoye OM: Study of the Combination Therapy of rt-PA and Eptifibatide to Treat Acute Ischemic Stroke (CLEAR-ER). 2009. http://clinicaltrials.gov/show/NCT00894803.
27. Adams HP Jr, Effron MB, Torner J, Davalos A, Frayne J, Teal P, Leclerc J, Oemar B, et al: Emergency administration of abciximab for treatment of patients with acute ischemic stroke: Results of an international phase III trial - Abciximab in Emergency Treatment of Stroke Trial (AbESTT-II). Stroke 2008; 39: 87- 99.
28. SPS3 Investigators, Benavente OR, Hart RG, McClure LA, Szychowski JM, Coffey CS, Pearce LA: Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. N Engl J Med 2012; 367: 817-825.
29. Lee KY: Comparison of Triflusal and Clopidogrel Effect in Secondary Prevention of Stroke Based on the Cytochrome P450 2C19 Genotyping (MAESTRO). 2010. http://clinicaltrials. gov/ct2/show/NCT01174693.
30. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995; 333: 1581- 1587.
31. Lee KY, Kim DI, Kim SH, Lee SI, Chung HW, Shim YW, Kim SM, Heo JH: Sequential combination of intravenous recombinant tissue plasminogen activator and intra-arterial urokinase in acute ischemic stroke. AJNR Am J Neuroradiol 2004; 25: 1470-1475.
32. Gan X, Luo Y, Ling F, Ji X, Chen J, Ding Y: Outcome in acute stroke with different intraarterial infusion rate of urokinase on thrombolysis. Interv Neuroradiol 2010; 16: 290-296.
33. Lee RS, Ok YC, Lim JS, Lim BC, Cho KY, Lee MC: Outcome evaluation of intravenous infusion of urokinase for acute ischemic stroke. Chonnam Med J 2012; 48: 52-56.
34. Horn J, de Haan RJ, Vermeulen M, Luiten PG, Limburg M: Nimodipine in animal model experiments of focal cerebral ischemia: A systematic review. Stroke 2001; 32: 2433-2438.
35. Zhang J, Yang J, Zhang C, Jiang X, Zhou H, Liu M: Calcium antagonists for acute ischemic stroke. Cochrane Database Syst Rev 2012; 5:CD001928.
36. Sydserff SG, Borelli AR, Green AR, Cross AJ: Effect of NXY-059 on infarct volume after transient or permanent middle cerebral artery occlusion in the rat: Studies on dose, plasma concentration and therapeutic time window. Br J Pharmacol 2002; 135: 103-112.
37. Marshall JW, Duffin KJ, Green AR, Ridley RM: NXY-059, a free radical-trapping agent, substantially lessens the functional disability resulting from cerebral ischemia in a primate species. Stroke 2001; 32: 190-198.
38. Sui H, Wang W, Wang PH, Liu LS: Protective effect of antioxidant ebselen (PZ51) on the cerebral cortex of stroke-prone spontaneously hypertensive rats. Hypertens Res 2005; 28: 249-254.
39. Sena E, Wheble P, Sandercock P, Macleod M: Systematic review and meta-analysis of the efficacy of tirilazad in experimental stroke. Stroke 2007; 38: 388-394.
40. Zhang N, Komine-Kobayashi M, Tanaka R, Liu M, Mizuno Y, Urabe T: Edaravone reduces early accumulation of oxidative products and sequential inflammatory responses after transient focal ischemia in mice brain. Stroke 2005; 36: 2220-2225.
41. Lee BJ, Egi Y, van Leyen K, Lo EH, Arai K: Edaravone, a free radical scavenger, protects components of the neurovascular unit against oxidative stress in vitro. Brain Res 2010; 1307: 22-27.
42. Lees KR, Zivin JA, Ashwood T, Davalos A, Davis SM, Diener HC, Grotta J, Lyden P, Shuaib A, Hardemark HG, Wasiewski WW, Stroke-Acute Ischemic NXY Treatment (SAINT I) Trial Investigators: NXY-059 for acute ischemic stroke. N Engl J Med 2006; 354: 588-600.
43. Shuaib A, Lees KR, Lyden P, Grotta J, Davalos A, Davis SM, Diener HC, Ashwood T, Wasiewski WW, Emeribe U: NXY-059 for the treatment of acute ischemic stroke. N Engl J Med 2007; 357: 562-571.
44. Ebselen Trial - Phase III. 2009. http://www. strokecenter.org/trials/ clinicalstudies/298.
45. van der Worp HB, Kappelle LJ, Algra A, Bar PR, Orgogozo JM, Ringelstein EB, Bath PM, van Gijn J, TESS Investigators, TESS II Investigators: The effect of tirilazad mesylate on infarct volume of patients with acute ischemic stroke. Neurology 2002; 58: 133-135.
46. Nakase T, Yoshioka S, Suzuki A: Free radical scavenger, edaravone, reduces the lesion size of lacunar infarction in human brain ischemic stroke. BMC Neurol 2011; 11: 39.
47. Mitta M, Goel D, Bansal KK, Puri P: Edaravone- Citicoline Comparative Study in Acute Ischemic Stroke (ECCS-AIS). J Assoc Physicians India 2012; 60: 36-38.
48. Sydserff SG, Cross AJ, Murray TK, Jones JA, Green AR: Clomethiazole is neuroprotective in models of global and focal cerebral ischemia when infused at doses producing clinically relevant plasma concentrations. Brain Res 2000; 862: 59-62.
49. Chaulk D, Wells J, Evans S, Jackson D, Corbett D: Long-term effects of clomethiazole in a model of global ischemia. Exp Neurol 2003; 182: 476-482.
50. Lyden P, Shuaib A, Ng K, Levin K, Atkinson RP, Rajput A, Wechsler L, Ashwood T, Claesson L, Odergren T, Salazar-Grueso E, CLASSI/H/T Investigators: Clomethiazole Acute Stroke Study in Ischemic Stroke (CLASS-I): Final results. Stroke 2002; 33: 122-128.
51. Miyabe M, Kirsch JR, Nishikawa T, Koehler RC, Traystman RJ: Comparative analysis of brain protection by N-methyl- D -aspartate receptor antagonists after transient focal ischemia in cats. Crit Care Med 1997; 25: 1037- 1043.
52. Grotta J, Clark W, Coull B, Pettigrew LC, Mackay B, Goldstein LB, Meissner I, Murphy D, LaRue L: Safety and tolerability of the glutamate antagonist CGS 19755 (Selfotel) in patients with acute ischemic stroke: Results of a phase IIa randomized trial. Stroke 1995; 26: 602-605.
53. Davis SM, Lees KR, Albers GW, Diener HC, Markabi S, Karlsson G, Norris J: Selfotel in acute ischemic stroke: Possible neurotoxic effects of an NMDA antagonist. Stroke 2000; 31: 347-354.
54. Schabitz WR, Li F, Fisher M: The N-methyl- D -aspartate antagonist CNS 1102 protects cerebral gray and white matter from ischemic injury following temporary focal ischemia in rats. Stroke 2000; 31: 1709-1714.
55. Nategh M, Shaveisi K, Shabanzadeh AP, Sadr SSh, Parviz M, Ghabaei M: Systemic hyperthermia masks the neuroprotective effects of MK-801, but not rosiglitazone in brain ischaemia. Basic Clin Pharmacol Toxicol 2010; 107: 724-729.
56. Kocaeli H, Korfali E, Ozturk H, Kahveci N, Yilmazlar S: MK-801 improves neurological and histological outcomes after spinal cord ischemia induced by transient aortic crossclipping in rats. Surg Neurol 2005; 64(suppl 2):S22-S26, discussion S27.
57. Albers GW, Goldstein LB, Hall D, Lesko LM, Aptiganel Acute Stroke Investigators: Aptiganel hydrochloride in acute ischemic stroke: A randomized controlled trial. JAMA 2001; 286: 2673-2682.
58. Turski L, Huth A, Sheardown M, McDonald F, Neuhaus R, Schneider HH, Dirnagl U, Wiegand F, Jacobsen P, Ottow E: ZK200775: A phosphonate quinoxalinedione AMPA antagonist for neuroprotection in stroke and trauma. Proc Natl Acad Sci USA 1998; 95: 10960-10965.
59. Suzuki M, Sasamata M, Miyata K: Neuroprotective effects of YM872 coadministered with t-PA in a rat embolic stroke model. Brain Res 2003; 959: 169-172.
60. Furukawa T, Hoshino S, Kobayashi S, Asakura T, Takahashi M, Atsumi T, Teramoto A: The glutamate AMPA receptor antagonist, YM872, attenuates cortical tissue loss, regional cerebral edema, and neurological motor deficits after experimental brain injury in rats. J Neurotrauma 2003; 20: 269-278.
61. Walters MR, Kaste M, Lees KR, Diener HC, Hommel M, de Keyser J, Steiner H, Versavel M: The AMPA antagonist ZK 200775 in patients with acute ischaemic stroke: A doubleblind, multicentre, placebo-controlled safety and tolerability study. Cerebrovasc Dis 2005; 20: 304-309.
62. A Study to Evaluate the Effects of YM872 on Stroke Lesion Volume in Acute Stroke Patients. 2002. http://clinicaltrials.gov/ct2/show/NCT00044070.
63. van der Worp HB, Sena ES, Donnan GA, Howells DW, Macleod MR: Hypothermia in animal models of acute ischaemic stroke: A systematic review and meta-analysis. Brain 2007; 130: 3063-3074.
64. de Georgia MA, Krieger DW, Abou-Chebl A, Devlin TG, Jauss M, Davis SM, Koroshetz WJ, Rordorf G, Warach S: Cooling for Acute Ischemic Brain Damage (COOL AID): A feasibility trial of endovascular cooling. Neurology 2004; 63: 312-317.
65. Hemmen TM, Raman R, Guluma KZ, Meyer BC, Gomes JA, Cruz-Flores S, Wijman CA, Rapp KS, Grotta JC, Lyden PD, ICTuS-L Investigators: Intravenous thrombolysis plus hypothermia for acute treatment of ischemic stroke (ICTuS-L): Final results. Stroke 2010; 41: 2265-2270.
66. Schwab S: Cooling plus Best Medical Treatment versus Best Medical Treatment Alone for Acute Ischaemic Stroke (EuroHYP- 1). 2013. http://clinicaltrials.gov/show/NCT01833312.
67. Macleod MR, Petersson J, Norrving B, Hacke W, Dirnagl U, Wagner M, Schwab S, European Hypothermia Stroke Research Workshop: Hypothermia for Stroke: Call to action 2010. Int J Stroke 2010; 5: 489-492.
68. Marinov MB, Harbaugh KS, Hoopes PJ, Pikus HJ, Harbaugh RE: Neuroprotective effects of preischemia intraarterial magnesium sulfate in reversible focal cerebral ischemia. J Neurosurg 1996; 85: 117-124.
69. Bradford A, Lees K: Design of the Intravenous Magnesium Efficacy in Acute Stroke (IMAGES) trial. Curr Control Trials Cardiovasc Med 2000; 1: 184-190.
70. Muir KW, Lees KR, Ford I, Davis S, Intravenous Magnesium Efficacy in Stroke (IMAGES) Study Investigators: Magnesium for acute stroke (Intravenous Magnesium Efficacy in Stroke trial): Randomised controlled trial. Lancet 2004; 363: 439-445.
71. Field Administration of Stroke Therapy - Magnesium (FAST-MAG) Trial. 2003. http://clinicaltrials.gov/show/NCT00059332.
72. Romanos E, Planas AM, Amaro S, Chamorro A: Uric acid reduces brain damage and improves the benefits of rt-PA in a rat model of thromboembolic stroke. J Cereb Blood Flow Metab 2007; 27: 14-20.
73. Amaro S, Soy D, Obach V, Cervera A, Planas AM, Chamorro A: A pilot study of dual treatment with recombinant tissue plasminogen activator and uric acid in acute ischemic stroke. Stroke 2007; 38: 2173-2175.
74. Amaro S, Canovas D, Castellanos M, Gallego J, Marti-Febregas J, Segura T, Chamorro A: The URICO-ICTUS study, a phase 3 study of combined treatment with uric acid and rtPA administered intravenously in acute ischaemic stroke patients within the first 4.5 h of onset of symptoms. Int J Stroke 2010; 5: 325- 328.
75. Rios C, Nader-Kawachi J, Rodriguez-Payan AJ, Nava-Ruiz C: Neuroprotective effect of dapsone in an occlusive model of focal ischemia in rats. Brain Res 2004; 999: 212-215.
76. Nader-Kawachi J, Gongora-Rivera F, Santos- Zambrano J, Calzada P, Rios C: Neuroprotective effect of dapsone in patients with acute ischemic stroke: A pilot study. Neurol Res 2007; 29: 331-334.
77. Dapsone for Acute Ischemia Stroke Study (DAISY). 2010. http://clinicaltrials.gov/show/NCT01144650.
78. Strbian D, Karjalainen-Lindsberg ML, Tatlisumak T, Lindsberg PJ: Cerebral mast cells regulate early ischemic brain swelling and neutrophil accumulation. J Cereb Blood Flow Metab 2006; 26: 605-612.
79. Strbian D, Tatlisumak T, Ramadan UA, Lindsberg PJ: Mast cell blocking reduces brain edema and hematoma volume and improves outcome after experimental intracerebral hemorrhage. J Cereb Blood Flow Metab 2007; 27: 795-802.
80. Treatment of Acute Stroke with Cromolyn (Single Dose). 2010. http://clinicaltrials.gov/ct2/show/NCT01175525.
81. Prinz V, Laufs U, Gertz K, Kronenberg G, Balkaya M, Leithner C, Lindauer U, Endres M: Intravenous rosuvastatin for acute stroke treatment: An animal study. Stroke 2008; 39: 433-438.
82. Montaner J, Ribo M, Jimenez C, Munoz F, Canovas D, Krupinski J, Martinez-Zabaleta M, de la Torre Laviana FJ, Freijo M, Segura T, Arenillas J, Flores JM, Alonso F, Vallejo JM, Borrego FR, Garcia JT, Martin AL, Anguiano YB, Roig XU, Garcia FP, Mederos RD: Stroke Treatment with Acute Reperfusion and Simvastatin. 2010. http://clinicaltrials.gov/show/NCT01073007.
83. Leger PL, de Paulis D, Branco S, Bonnin P, Couture-Lepetit E, Baud O, Renolleau S, Ovize M, Gharib A, Charriaut-Marlangue C: Evaluation of cyclosporine A in a stroke model in the immature rat brain. Exp Neurol 2011; 230: 58-66.
84. Nighoghossian N: Neuroprotection Impact of Cyclosporin A in Cerebral Infarction (CsAStroke). 2012. http://clinicaltrials.gov/show/NCT01527240.